Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity.
Sotzny, Franziska, Filgueiras, Igor Salerno, Kedor, Claudia et al. · Frontiers in immunology · 2022 · DOI
Quick Summary
This study looked at whether certain antibodies in the blood—proteins the immune system makes that sometimes attack the body's own tissues—might explain why some people with long COVID develop ME/CFS symptoms like severe fatigue and blood flow problems. Researchers compared antibody levels in 80 patients with long COVID (40 with ME/CFS) against healthy people and found that patients had different patterns of these antibodies, particularly ones affecting blood vessels and the nervous system. The severity of fatigue and blood pressure/temperature regulation problems seemed connected to lower levels of a specific antibody (ADRB2), suggesting the immune system's dysregulation may play a role in these symptoms.
Why It Matters
Understanding the immune mechanisms underlying ME/CFS is critical since the disease remains poorly understood and many patients lack objective biomarkers for diagnosis. This study provides evidence that dysregulated antibodies targeting autonomic nervous system and vascular control receptors may contribute to ME/CFS symptoms, potentially opening new avenues for diagnostic testing and targeted therapies. The findings help validate that ME/CFS has biological underpinnings rather than being purely psychological.
Observed Findings
PCS/ME/CFS patients showed lower levels of various autoantibodies compared to at least one control group, with altered correlational patterns among autoantibodies.
Autoantibodies targeting ADRB2, STAB1, and ADRA2A were identified as the strongest classifiers distinguishing post-COVID disease outcomes.
Severity of fatigue in PCS/ME/CFS patients correlated with ADRB2 autoantibody levels.
Vasomotor symptoms (blood pressure/temperature regulation) in PCS/ME/CFS patients were associated with ADRB2 autoantibody levels.
Dysregulation patterns affected autoantibodies involved in autonomic nervous system, vascular, and immune regulation.
Inferred Conclusions
Dysregulation of autoantibodies against receptors controlling the autonomic nervous system and vascular function is a feature of PCS and ME/CFS pathogenesis.
Autoantibody profiles—particularly ADRB2-targeting antibodies—may help classify post-COVID outcomes and could serve as biological markers of disease.
The correlation between specific autoantibodies and symptom severity suggests immune dysregulation contributes mechanistically to fatigue and vasomotor symptoms in ME/CFS.
Remaining Questions
Do these autoantibodies functionally impair receptor signaling, and if so, what are the downstream pathophysiological consequences?
What This Study Does Not Prove
This study does not prove that these autoantibodies cause ME/CFS symptoms—it only shows correlations, and correlation does not equal causation. The cross-sectional design prevents determination of whether antibody dysregulation precedes, follows, or is independent of symptom onset. The study also does not establish whether these antibodies are specific to ME/CFS or whether they functionally impair receptor signaling in patients' tissues.